Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that tumor cell killing by cytotoxic chemotherapy exposes the
immune system to high levels of tumor antigens.The combination of Paclitaxel/Carboplatin and
Pembrolizumab may result in deeper and more durable responses compared with standard
chemotherapy alone.